FDA rejects Adamis' emergency treatment for severe allergic reaction
June 06, 2016 at 07:10 AM EDT
June 6 (Reuters) - Adamis Pharmaceuticals Corp said the U.S. Food and Drug Administration rejected its emergency treatment for a severe, potentially fatal allergic reaction or acute anaphylaxis.
